

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Protocol for Process Evaluation of an integrated community and primary healthcare worker intervention for management of Common Mental Disorders in India: The Systematic Medical Appraisal, Referral and Treatment (SMART) Mental Health Cluster Randomized Control Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058669
Article Type:	Protocol
Date Submitted by the Author:	28-Oct-2021
Complete List of Authors:	<p>Mukherjee, Ankita; The George Institute for Global Health India, Daniel, Mercian; The George Institute for Global Health India Kallakuri, Sudha; The George Institute for Global Health Kaur, Amanpreet; The George Institute for Global Health India Devarapalli, Siddhardha; The George Institute for Global Health India Raman, Usha; University of Hyderabad, Department of Communication Thornicroft, Graham; King's College London Institute of Psychiatry Psychology and Neuroscience, Centre for Global Mental Health Centre for Implementation Science, Health Service and Population Research Department</p> <p>Essue, Beverley; University of Toronto Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation Praveen, D; The George Institute for Global Health India; University of New South Wales</p> <p>Sagar, Rajesh; All India Institute of Medical Sciences, Department of Psychiatry</p> <p>Kant, Shashi; All India Institute of Medical Sciences, Community Medicine</p> <p>Saxena, Shekhar; Harvard University T H Chan School of Public Health Patel, Anushka; George Institute for Global Health; University of New South Wales</p> <p>Peiris, David; The George Institute for Global Health; University of New South Wales,</p> <p>Maulik, Pallab; The George Institute for Global Health India; University of New South Wales</p>
Keywords:	MENTAL HEALTH, PRIMARY CARE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protocol for Process Evaluation of an integrated community and primary healthcare worker intervention for management of Common Mental Disorders in India: The Systematic Medical Appraisal, Referral and Treatment (SMART) Mental Health Cluster Randomized Control Trial

AUTHORS

Ankita Mukherjee¹, Mercian Daniel¹, Sudha Kallakuri², Amanpreet Kaur¹, Siddhardha Devarapalli², Usha Raman⁶, Graham Thornicroft⁷, Beverly M. Essue⁵, Praveen Devarasetty², Rajesh Sagar⁸, Shashi Kant⁸, Shekhar Saxena⁹, Anushka Patel³ and David Peiris³, Pallab K Maulik^{1,4}.

Corresponding Author: Pallab K Maulik, pmaulik@georgeinstitute.org.in

ABSTRACT

Introduction

In India about 95 % of individuals who need treatment for common mental disorders (CMDs) like depression, stress and anxiety and substance use are unable to access care. Stigma associated with help seeking and lack of trained mental health professionals are important barriers in accessing mental health care. SMART Mental Health integrates a community-level stigma reduction campaign and task sharing with the help of a mobile-enabled electronic decision support system (EDSS)- to reduce psychiatric morbidity due to stress, depression, and self-harm in high risk individuals. This paper presents and discusses the protocol for process evaluation of SMART Mental Health.

Methods and Analysis

We will use mixed quantitative and qualitative methods to evaluate implementation fidelity, identify facilitators of and barriers to implementation of the intervention, perceptions about effectiveness and acceptability of intervention components by different stakeholders, explain variations in outcomes and unexpected consequences across sites and explain any adaptations to the intervention during the study and their possible impact on the outcomes. The design and analysis will be guided by Medical Research Council (MRC) framework for process evaluations, the RE-AIM framework, and the Normalisation Process Theory.

Ethics and Dissemination

1
2
3 The study has been approved by the ethics committee of the George Institute for Global
4 Health, India and the Institutional Ethics Committee, All India Institute of Medical Sciences
5 (AIIMS), New Delhi.
6
7

8
9 Findings of the study will be disseminated through peer reviewed publications, stakeholder
10 meetings, digital and social media platforms.
11
12

13 **Trial Registration number:**

14
15
16 The trial has been registered with the Clinical Trial Registry-India (CTRI) -
17 CTRI/2018/08/015355
18
19

20 **Strengths and Limitations of the Study**

- 21 • A strength of our study is its use of implementation science theories and guidelines
22 for process evaluation to frame the study design
- 23 • This study combines data from an open source medical record system (OpenMRS)
24 with qualitative methods to understand trends, patterns, and differences in
25 outcome
- 26 • One limitation could be the overlap between the implementation team and the
27 evaluation team.
28
29
30
31
32
33
34
35

36 **INTRODUCTION**

37
38 India has a significant burden of mental disorders with an estimated 115 million people in
39 need of mental health care.¹ The National Mental Health Survey of India (2015-16) found
40 substance use, depressive disorders, and anxiety disorders to be prevalent in about 10% of
41 the population.¹ Despite the significant burden, access to mental health services is severely
42 limited and it is estimated that nearly 95% of individuals with common mental disorders
43 (CMDs) are unable to access care in India² leading to large treatment gaps. Studies report that
44 in low- and middle-income countries (LMICs), the treatment gap for any mental disorder is
45 between 75-85%.³ One study found that in low-resource settings such as India, only one in
46 every 27 individuals with depression who recognised need for treatment, could access
47 minimally adequate treatment from a trained mental health professional.⁴
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 This large treatment gap is due to several factors, on both demand and supply sides. Low
4 awareness about mental health in the community and high level of stigma related to mental
5 illness are key demand side factors for poor help-seeking for CMDs.⁵ On the supply side,
6 several systemic barriers limit access to mental health services. Among these are the lack of
7 a trained mental health workforce and absent/minimal mental health services at the primary
8 care level, inadequate supply of psychotropic drugs at primary health care facilities, and
9 limited budget for mental health care.⁶

10
11 Our formative research has demonstrated that addressing both supply and demand side
12 factors by conducting a community-based anti-stigma campaign and implementing a
13 technology-enabled mental health services delivery model by primary health workers, has the
14 potential to increase access to mental health care for those at risk of CMDs and reduction in
15 depression and anxiety scores.⁷⁻¹⁰ In this research, task sharing by primary health workers
16 helped facilitate the process, and technology was seen as an enabling factor in streamlining
17 delivery of mental health care.¹⁰

18
19 Based on these findings, we developed SMART Mental Health- a hybrid effectiveness-
20 implementation cluster randomized controlled trial (cRCT) that is being implemented in two
21 Indian states. The cRCT protocol is available elsewhere.¹¹ The goal of SMART Mental Health is
22 to reduce psychiatric morbidity due to stress, depression, and self-harm in individuals
23 identified at high risk of these conditions. The co-**primary outcomes** are:

- 24
25 (1) the mean difference in PHQ-9 scores at 12 months in people identified at high-risk of CMDs;
26
27 (2) the difference in mean behaviour scores at 12 months in the total population.

28
29 In this paper, we outline the protocol for a process evaluation of the SMART Mental Health.
30 Process evaluations provide important insights into *how* an intervention is implemented,
31 leading to understanding what strategies either worked or did not work, explaining
32 differences in outcome, and to gain insights into the experience of the target population for
33 whom the intervention was designed. The aims of the process evaluation are to:

- 34
35 1. Assess implementation fidelity and understand how the intervention was implemented
36
37 2. Understand perceptions about effectiveness and acceptability of intervention components
38
39 by different stakeholders

3. Identify and explain facilitators of and barriers to implementation of the intervention
4. Explain variations in outcomes and unexpected consequences across sites
5. Explain any adaptations to the intervention during the study and their possible impact on the outcomes

METHODS AND ANALYSIS

Theoretical Framework

The process evaluation has been integrated into the cRCT design with an early formative study conducted to understand the feasibility of implementing the project components. It draws on multiple theories and frameworks (Table 1). The Medical Research Council (MRC) guidelines for process evaluation will provide an overall conceptual framework¹². According to this framework, the three broad areas of enquiry in a process evaluation are ‘*implementation*’ (what is implemented and how) ; ‘*mechanism of impact*’ – (how intervention produces change) and ‘*context*’ – (how context affects implementation and outcomes). The framework also emphasises the need to spell out the key causal assumptions made in the programme theory.

Table 1: Theories to be used in the study

THEORY	ABOUT THEORY	PURPOSE OF USING THE THEORY
<i>Theory guiding overall design and conceptual framework of the process evaluation</i>		
MRC Framework ¹³	A framework for designing and carrying out process evaluation of complex interventions. Process evaluation should answer questions related to three components: <i>Implementation</i> (what is delivered and how?) <i>Mechanisms of impact</i> (how does the delivered intervention produce change?) and <i>Context</i> (how does context affect implementation and outcomes?) Along with the context and the mechanism of impact, it emphasises the need to spell out the key <i>causal assumptions</i> or the programme theory.	The framework is used to provide the overall conceptual design of the process evaluation. The three components (implementation, mechanism of impact and context) will be the broad areas of inquiry in the process evaluation.
<i>Theories that will inform specific domains of inquiry in the study</i>		

1 2 3 4 5 6 7 8 9	REAIM ¹⁴	A framework which provides five key dimensions on which a behaviour change intervention can be evaluated. These include Reach, Effectiveness, Adoption, Implementation and Maintenance of an intervention.	The framework will be used to evaluate the 'Implementation' component of the programme.
10 11 12 13 14 15 16 17 18 19 20 21 22	Normalisation Process Theory ¹⁵	A theory which focuses on how complex interventions become 'normalised' or embedded in routine practice. It helps to understand facilitators and barriers in adoption and routinisation of an intervention. Includes four main components: <i>coherence (sense making), cognitive participation (engagement), collective action (work done for intervention to happen), and reflexive monitoring (taking measure of costs and benefits of the intervention).</i>	The model will be used to explain differences in routinisation of mHealth component in the post-trial maintenance phase.

23
24
25 We will also use the RE-AIM framework¹⁴ to understand and describe the reach, effectiveness, adoption, implementation and maintenance of the intervention. The Normalisation Process Theory (NPT)¹⁵ will help to understand the factors that influence integration and routinisation (becoming part of routine practice) of novel interventions in specific settings. NPT is grouped into four broad sub-constructs which influence normalisation or routinisation of novel interventions (coherence, cognitive participation, collective action, and reflexive monitoring). REAIM and NPT will be used to evaluate how the program was implemented to understand barriers to and facilitators of its routine use by PHC doctors, ASHAs and community participants.

30
31
32
33
34
35
36
37
38
39
40 Broad thematic areas of inquiry will include the *context, implementation, and mechanism of impact* (Table 2). Under the theme 'context', social, political, cultural and health system level factors impacting on implementation of the intervention will be explored. Differences between the sites, programme adaptations that were a result of change in context (for example the COVID-19 pandemic), and site-specific barriers and facilitators that impacted the programme implementation and outcome will be enquired into. Under 'implementation' the process evaluation will assess the implementation of the two intervention components - anti stigma campaign and mHealth based service delivery- using the REAIM parameters. It will also investigate the experiences of end users of the intervention. Finally, the process evaluation will explore the 'mechanism of impact' by critically examining any variations in outcomes or unexpected outcomes.

Table 2. Conceptual Framework for Process Evaluation

Broad Area of Enquiry	Domains of Inquiry	Key Questions/Process Measures	Data Source
CONTEXT	Differences in context	<ul style="list-style-type: none"> • What are the differences in social, economic, cultural and health system level, between the sites and among the clusters? • Do contextual differences influence how program is delivered in different settings? 	Secondary data; Formative research data Interview with project staff
	Significant changes in context and programme adaptations	<ul style="list-style-type: none"> • What are some of the key contextual factors which influenced the overall implementation of the intervention (e.g. COVID-19 pandemic)? • What were some of the context specific adaptations that were made to address emerging challenges? 	Interview with project staff Project documentation on operational challenges
	Barriers and Facilitators	<ul style="list-style-type: none"> • What are some major barriers faced in implementing the intervention components? • What are some of the factors which acted as facilitators in implementation of the intervention components (anti-stigma campaign, mHealth, training and capacity building)? 	Interview with project staff
IMPLEMENTATION	Implementation fidelity	Was the intervention delivered as it was planned?	Program records and documents; Observation and rating Interview with project staff

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	<p>Intervention Reach</p>	<ul style="list-style-type: none"> • What was the coverage of the different <i>anti-stigma campaign</i> methods, in terms of: <ul style="list-style-type: none"> - Total persons reached (including gender-wise break-up) - Villages and clusters covered - Number and proportion of high-risk cohort reached - Number and proportion of non-high-risk cohort reached - Key stakeholders reached • What was the reach of the mHealth services in terms of : <ul style="list-style-type: none"> - Number and proportion of high-risk cohort in the intervention arm provided counselling or follow-up services by ASHAs? - Number and proportion persons from high-risk cohort provided services in village level health camps - Number and proportion of high-risk cohort from the intervention arm who sought care at the PHC - Number and proportion high risk-cohort from the control arm who sought care for CMDs • What was the reach of IVRS messages to ASHAs and high- risk individuals in terms of <ul style="list-style-type: none"> - Total calls made - Calls completed as proportion of total calls - Calls not picked up as proportion of total calls 	<p>Project records and documents</p> <p>Backend data</p> <p>Interview with project staff</p> <p>Interview with ASHAs</p>
--	---------------------------	---	--

		<ul style="list-style-type: none"> - Average time of a call made 	
		<ul style="list-style-type: none"> • Did the ASHAs face any challenge in reaching out to any category of high-risk individual in their village? 	
	Intervention effectiveness	<ul style="list-style-type: none"> • What was the perception of the community and key stakeholders about the utility effectiveness content of the IEC materials the anti-stigma? • What are some of the key take home messages that people absorbed from the campaign? • What was the perception of ASHAs about impact of anti-stigma campaign in their village? • What is the association between exposure to anti stigma content with changes in KAB scores and care seeking? • What is the perception of ASHAs about effectiveness of technology health mental health service delivery in managing CMD in the community? • What is the perception of PHC doctors about effectiveness of technology health mental health service delivery in managing CMD in the community? • What was the perception of ASHAs about the utility of messages received through IVRS? 	<p>Community satisfaction survey done at the end of drama performance</p> <p>Outcome survey data; Backend data; FGD with community members</p> <p>Interview with community leaders (like elected village heads, influential village elders and religious leaders),</p>
	Intervention acceptability and adoption	<ul style="list-style-type: none"> • What was the perception of ASHAs about using EDSS for providing care (challenges, perceived benefits, potential for routine use of mHealth)? 	<p>Backend data</p> <p>Interview with ASHAs</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		<ul style="list-style-type: none"> • What was the perception of PHC doctors about using EDSS for providing care (challenges, perceived benefits, potential for routine use of mHealth)? • What were the patterns of use of EDSS by ASHAS in terms of : <ul style="list-style-type: none"> - Average time take by ASHAs to administer GAD7 and PHQ 9 over time (during screening, during monitoring) - Association between gender of high-risk patient and average time taken by ASHAs to complete screening - Association between GAD7 and PHQ 9 scores and average time taken to complete test by ASHAs - Cluster-wise difference in average time taken by ASHAs to administer GAD7 and PHQ 9 - Association between ASHA’s age and education with average time taken to administer GAD 7 and PHQ9 • What were some key features of use of EDSS by PHC doctors in terms of: <ul style="list-style-type: none"> - Average time taken for diagnosis and identification of treatment plan using mhGAP over time - Association between type of CMD and time taken for diagnosis and identification of treatment plan using 	<p>FGD with ASHAs; Interview with doctors</p> <p>Interview with PHC support staff</p> <p>Interview with health officials (ASHA co-ordinator, CMO)</p> <p>Patient interview</p>
--	--	--	--

		<p>mhGAP</p> <ul style="list-style-type: none"> • What was the perception of high-risk patients about ease of getting treatment through mHealth? 	
	<p>Post-trial maintenance</p>	<ul style="list-style-type: none"> • What was the proportion of ASHAs who continued to provide routine care compared to those who discontinued? • What are the factors which explain differences in the uptake of the intervention among ASHAs? • To what extent is patient adherence associate with routine care and follow-up provided by the ASHAs • What are the cluster level differences in number of CMD patients provided treatment during the post-trial phase? What are the factors which explain these differences? • To what extent has use of EDSS become routine practice among PHC doctors? • What are factors explain differences in adoption/ routinisation of EDSS in different PHC clusters? 	<p>Backend data</p> <p>Interview with ASHAs</p> <p>Interview with PHC doctors</p> <p>Interview with PHC support staff</p> <p>Interview with project staff</p>
	<p>Health service use</p>	<p>What are the barriers or facilitators that patient from intervention cluster face while accessing care in the PHC?</p> <p>How many high-risk individuals identified in the intervention arm did not seek care? What are factors which can explain this?</p>	<p>Backend data</p> <p>Interview with high-risk individuals</p> <p>Interview with ASHAs</p> <p>Interview with doctor</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

		<p>What are the factors which explain treatment adherence among high-risk patients who sought care?</p> <p>What are the cluster-wise differences in service utilisation, treatment adherence and number of referrals to specialist centres? What are the factors which can explain this?</p>	<p>Interview with project staff</p>
MECHANISM OF IMPACT	Variation in outcomes	<p>What kind of cluster level variation is overserved in in the outcomes? What works, for whom and in what context?</p>	<p>Outcome data</p> <p>Backend data;</p> <p>Interview with ASHAs</p> <p>Interview with doctor</p> <p>Interview with project staff</p>
	Unexpected outcomes	<p>What are some unexpected outcomes and what factors can be attributed to them?</p>	<p>Outcome data</p> <p>Backend data;</p> <p>Interview with ASHAs</p> <p>Interview with doctor</p> <p>Interview with project staff</p>

Study setting

SMART Mental health is being implemented in 133 villages serviced by 44 randomly selected Primary Health Centres (PHC) in West Godavari district of Andhra Pradesh (South India) and Palwal and Faridabad districts of Haryana (North India).

Study design

The process evaluation will use a mixed-method multiple case study design with PHC clusters constituting a 'case'. Up to eight case studies will be included. Each case will be selected purposively based on the principle of maximum variation in terms of health service delivery context, implementation challenges and outcomes.

Intervention Description

The intervention comprises two key components; an anti-stigma campaign, and a technology-enabled mental health service intervention delivered through task sharing. The capacities of community health workers known as Accredited Social Health Activists (ASHAs) and PHC doctors will be enhanced, by providing training in identifying and managing stress, depression, or suicide risk using a technology enabled decision support system (Figure 1).

[INSERT] FIGURE 1. INTERVENTION PROTOTYPE OF SMART MENTAL HEALTH¹¹

In the ***pre-intervention phase*** ASHAs will be trained to use the EDSS to screen individuals at high risk of stress, depression, self-harm, or suicide using digital hand-held tablets. The tablets have two pre-installed, standardised screening and assessment tools- the Patient Health Questionnaire-9 (PHQ9)^{16 17} and the Generalized Anxiety Disorder -7 (GAD-7)^{17 18} questionnaire. The screening process classifies whether participants are at high risk of CMDs based on the PHQ-9 and GAD-7 scores. Because a substantial proportion of people at risk of CMDs undergo natural remission over a period of time¹⁹ a second screening of all people initially identified at high risk is undertaken by the ASHAs within six months of the first screening to identify those who remain at 'high risk'.

1
2
3 Additionally, a Knowledge Attitude Behaviour (KAB)²⁰ scale is administered to assess levels
4 of stigma associated with mental disorders in the community, a Barrier to Access to Care
5 Evaluation–Treatment Stigma (BACE-TS)²¹ questionnaire to assess stigma perceptions
6 related to help-seeking for mental disorders and the EuroQol five-dimension scale (EQ-5D-
7 3L)²² to assess quality of life. Questions related to history of psychiatric morbidity,
8 availability of social network/support, treatment history and costs incurred in treatment
9 (which will be used for economic evaluation) are also asked.

10
11
12 In the **intervention phase** the two major intervention components will be implemented to
13 those PHCs randomised to receive SMART Mental Health. The logic model for how the
14 intervention strategy is hypothesised to meet its aims has been provided (Figure 2.).
15
16
17
18
19
20
21
22
23
24

25 [INSERT] FIGURE 2. LOGIC MODEL OF SMART MENTAL HEALTH
26
27
28
29

30 The anti-stigma campaign uses audio-visual and print material tailored to the local
31 community and delivered to both high-risk and non-high-risk individuals, with the aim of
32 reducing negative knowledge, attitudes and behaviours related to mental disorders. The
33 second component of the intervention is a technology enabled mental health service
34 delivery model. An mHealth platform will be used for screening, diagnosis, referral, and
35 management of CMDs by community level health workers (ASHAs) and PHC doctors. Health
36 workforce capacity building is a crucial input which will be embedded throughout the
37 intervention. The ASHAs will follow-up individuals at high-risk of CMDs to support access to
38 care from the PHC doctors. When the patient reaches the PHC, the doctors will use an EDSS
39 based on World Health Organization’s Mental Health Gap Action Programme Intervention
40 Guide (mhGAP-IG)²³. Clinical data will be shared between the ASHAs and doctors using a
41 secure cloud-based server. For follow-up care, the ASHAs will have an algorithm enabled
42 priority listing that will provide them with a traffic-light system to prioritise and track the
43 progress of individuals in her village. They will use this to follow up patients, paying
44 particular attention to the highest priority individuals, and enquiring about their treatment
45 adherence and mental well-being.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Following the intervention, a **post-intervention phase** up to 9 months will assess the
4 sustainability of the intervention without external influence of the trial team. In this phase,
5 the components of the intervention will be rolled out in the control arm too. Support for
6 ASHAs and doctors by project staff will be minimal. Staff will assist ASHAs and doctors to
7 resolve any technical problems with the tabs and provide initial support and troubleshoot
8 any issues.
9
10
11
12
13

14 *Control arm*

15
16
17 In the control arm ASHAs will be provided with the names of individuals at high risk of CMDs
18 and they will support those individuals to seek care and provide them with relevant
19 information of mental health care providers. PHC doctors in the control arm will be informed
20 that there may be patients who may seek care for CMDs. The ASHAs and the doctors in the
21 control arm will not be provided with access to the EDSS. The anti-stigma campaign will be
22 delivered in a less extensive manner. Besides pamphlets and brochures, all the other anti-
23 stigma components will be shared with the study participants. The live drama shows however,
24 will not be conducted. Only videos of the drama will be shown. The ASHAs will draw on their
25 existing training and experience on mental health to support individuals as needed.
26
27
28
29
30
31
32
33

34 **Data Collection**

35
36
37 Quantitative data source includes analysis of the trial outcomes and usage analytics extracted
38 from the mHealth platform. This includes (1) user metrics from each tablet used by ASHAs
39 and PHC doctors; (2) screening, and treatment data about each high-risk individual in the
40 intervention cohort; (3) data from the priority listing application (used by ASHAs) which
41 provide information on treatment status and high-risk individuals who need to be followed-
42 up; and (4) data from the interactive voice recorded system used to send messages to ASHAs
43 and high-risk individuals (to facilitate treatment adherence and follow-up). These data will be
44 used to assess reach, effectiveness, adoption, maintenance, and service utilisation of the
45 intervention.
46
47
48
49
50
51
52

53
54 Qualitative data will include key informant interviews and focus group discussions with PHC
55 doctors, ASHAs, hospital administrators, service users and any other relevant stakeholders
56 such as family members of service users and community leaders. The qualitative study data
57 will explore perceptions of key stakeholders about the effectiveness and acceptability of
58
59
60

intervention components and challenges in implementation. A detailed data collection plan has been discussed below (Table 3).

Table 3: Qualitative Data Collection Plan

Focus Group Discussions			
Type of Group/Individual	Some areas of inquiry	Number planned per PHC	Total Planned (8 PHCs will be selected for the case study)
ASHAs	<ul style="list-style-type: none"> Facilitators and barriers experienced in delivering the intervention in the community Perception about effectiveness of different intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Perceptions on training appropriateness, effectiveness and methods Factors that influenced treatment seeking by high-risk cohort Overall experience of participating in the trial 	1	8
Project Field staff	<ul style="list-style-type: none"> Barriers or facilitators experienced in implementation of the intervention Perceived factors which explain high/low treatment seeking in different PHCs Key challenges and lessons learnt in implementation of intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Views on impact of the intervention in the community Perceptions on training appropriateness, effectiveness and methods 	1	8
Study participants from high-risk cohort in intervention arm who sought treatment	<ul style="list-style-type: none"> Perceptions about different intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Facilitators and barriers in treatment seeking Experience of care and perception about quality of care Positive/negative experiences as a study participant Perception about benefits/effectiveness of the intervention 	1	8
Study participants from high-risk cohort in intervention arm	<ul style="list-style-type: none"> Perceptions about different intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS 	1	8

1 2 3 4 5 6 7 8 9	who did not seek treatment)	<ul style="list-style-type: none"> • Reasons for not seeking care • Facilitators and barriers in treatment seeking • Positive/negative experiences as a study participant • Perception about benefits/effectiveness of the intervention 		
10 11 12 13 14 15 16 17 18 19	Study participants from high-risk cohort in the control arm (including both who sought treatment and who did not seek treatment)	<ul style="list-style-type: none"> • Reasons for seeking or not seeking care • Facilitators and barriers in the community to seeking care for CMDs • Experience as a study participant 	1	8
20	TOTAL FGDs			40
21	In-Depth Interviews			
22	PHC doctors from intervention arm	<ul style="list-style-type: none"> • Experience of using technology-based decision support system to diagnose and manage CMDs • Challenges faced in trial participating • Perceived effectiveness of intervention components (anti-stigma campaign, mHealth) in improving management of CMDs in the community. • Possible facilitators and barriers to scaling up • Overall experience of participating in the trial 	1	8
23 24 25 26 27 28 29 30 31 32 33	Village Heads/community leaders of the village	<ul style="list-style-type: none"> • Their role in this programme if any • Views about the programme and its impact • Feedback and suggestion if any 	1	8
34 35 36 37 38	Study participants from high-risk cohort in intervention arm who visited the doctor and were given medical and/or psychological treatment	<ul style="list-style-type: none"> • Experience of seeking care from PHC doctor and perception about quality of care • Perceived benefit if any as a result of treatment • Barriers and facilitators for seeking treatment from a specialist • Positive/negative experiences as a study participant • Suggestions for the programme 	1	8
39 40 41 42 43 44 45 46 47 48 49 50	Study participants from high-risk cohort in intervention arm who visited the doctor and were referred to a specialist	<ul style="list-style-type: none"> • Experience of seeking care from specialist and perception about quality of care • Perceived benefit if any as a result of treatment • Barriers and facilitators for seeking treatment from a specialist • Positive/negative experiences as a study participant • Suggestions for the programme 	1	8
51 52 53 54 55 56 57 58 59				

Study participants who discontinued prescribed treatment after one visit to the doctor	<ul style="list-style-type: none"> • Reasons for seeking care • Reasons for discontinuing care • Facilitators and barriers for seeking treatment for CMDs in the community • Overall experience of participating in the trial 	1	8
Government health officials	<ul style="list-style-type: none"> • Perception about effectiveness of the intervention in reducing treatment gap for CMDs • Perceived facilitators and challenges in scaling up the intervention • Their role if any in the programme 	4 (per district)	12
Total Interviews			52

At the end of the post-intervention phase, a detailed comparative case study of two PHCs will be undertaken. It will include one PHC with high utilisation of EDSS and one with low utilisation. The case study will provide insights into barriers and facilitators in adoption and routinisation of EDSS and explain differences in levels of utilisation of mHealth in different PHC clusters. Interviews with all key stakeholders (including PHC doctors, ASHAs, supervisors associated with the PHC) will be used to develop the case study.

Data Analysis

For quantitative data, basic descriptive analyses will initially be conducted and, where appropriate, multi-level statistical models will be developed to understand associations between various individual and PHC level parameters and implementation outcomes to enable us to identify the most important factors which impact the outcomes. For qualitative data analysis interview transcripts will be read independently by two persons. A priori codes based on the conceptual framework (Table 2) will be used to code the data. Additional thematic findings emerging through the data will be added to the coding framework. Data will be coded using NVivo 12.0. Both qualitative and quantitative data across case studies will be triangulated to arrive at the findings.

PATIENT AND PUBLIC INVOLVEMENT

In the formative phase, community feedback was sought through FGDs, to make anti-stigma content culturally and contextually relevant. The study findings will be shared with public.

1
2
3 Findings will be disseminated through publication in peer reviewed journals, meetings, digital
4 and social media platforms.
5
6

7 **ETHICS AND DISSEMINATION**

8
9
10 SMART Mental Health cRCT was approved by the George Institute for Global Health, India and
11 the Institutional Ethics Committee (IEC), All India Institute of Medical Sciences (AIIMS), New
12 Delhi. The trial has been registered (CTRI/2018/08/015355) with the Clinical Trial Registry-
13 India, National Institute of Medical Statistics, Indian Council of Medical Research (ICMR). The
14 project has received requisite approval the Health Ministry's Screening Committee (HMSC),
15 ICMR.
16
17
18
19
20

21 **TRIAL STATUS**

22
23
24 At the time of writing this paper, the intervention phase of the trial had begun in both sites.
25 Clinical Trials Registration was completed on 16th August 2020. Randomization of clusters in
26 Haryana was done on 21st September 2020 and in Andhra Pradesh on 4th December 2020. Key
27 intervention components are being delivered in Andhra Pradesh and post intervention
28 activities and follow-up surveys are being planned in Haryana.
29
30
31
32
33

34 **CONCLUSION**

35
36 SMART Mental Health is a complex intervention which will be delivered in two sites with
37 contextual diversity and multiple stakeholders, using a combination of anti-stigma and
38 mHealth tools, to improve access to and uptake of mental health care. This process evaluation
39 will provide a thorough understanding of the factors that impacted the implementation of
40 this complex intervention, the achievement of outcomes and the key processes and
41 adaptations required. This will not only contribute to a more rigorous evaluation of the trial,
42 but it will also prove useful for future efforts to replicate the programme in India and will be
43 of relevance to other low- and middle-income countries.
44
45
46
47
48
49
50

51 **Authors' Affiliation**

52
53
54 ¹The George Institute for Global Health, New Delhi, India. ²The George Institute for Global Health,
55 Hyderabad, India. ³The George Institute for Global Health, UNSW Sydney, Sydney, Australia.
56
57
58
59 ⁴University of New South Wales, Sydney, Australia. ⁵ Institute for Health Policy, Management and
60

1
2
3 Evaluation, University of Toronto, Toronto, Canada. ⁶ Department of Communication, University of
4
5 Hyderabad, Hyderabad, India. ⁷Centre for Global Mental Health and Centre for Implementation
6
7 Science, Health Service and Population Research Department, Institute of Psychiatry, Psychology and
8
9 Neuroscience, King's College London, London, UK. ⁸ All India Institute of Medical Sciences, New Delhi,
10
11 India, ⁹Harvard T H Chan School of Public Health, Boston, USA.
12
13
14

15 **Contributors**

16
17 DP, PKM and AP conceptualised the SMART Mental Health Trial with a process evaluation in mind.
18
19 AM developed this process evaluation protocol with extensive and significant inputs from PKM and
20
21 DP. PKM and DP commented on multiple drafts before sending a prefinal version to everyone listed
22
23 as authors. All authors provided critical intellectual inputs and comments to the draft. PKM leads the
24
25 implementation of the trial in India along with MD,SD, SKI, AK and AM. All authors contribute to
26
27 science or operationalising of the project as co-investigators, or as steering committee members, or
28
29 researchers helping in the implementation of the trial. Each author has critically reviewed,
30
31 commented and approved the final manuscript.
32
33
34
35

36 **Funding**

37
38 This research is supported by an Australian National Health and Medical Research Council (NHMRC)
39
40 Global Alliances for Chronic Disease Grant (APP1143911). There is no role of the funding body in the
41
42 design of the study and the conceptualisation and writing of the manuscript.
43
44
45

46 **Competing Interest statement**

47
48 The George Institute has a part-owned social enterprise, George Health Enterprises, which has
49
50 commercial relationships involving digital health innovations.
51

52
53 PKM is partially supported through NHMRC/GACD grant (SMART Mental Health-APP1143911) and
54
55 UKRI/MRC grant MR/S023224/1 - Adolescents' Resilience and Treatment nEeds for Mental health in
56
57 Indian Slums (ARTEMIS). MD, SD, SKI, AK, AM and DP are partially or wholly supported through the
58
59 SMART Mental Health NHMRC/GACD grant. DP is supported by fellowships from the National Health
60

and Medical Research Council of Australia (1143904) and the Heart Foundation of Australia (101890). AK is partially supported by Indigo Partnership (MR/R023697/1) award. GT is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London at King's College London NHS Foundation Trust, and by the NIHR Asset Global Health Unit award. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. GT is also supported by the Guy's and St Thomas' Charity for the On Trac project (EFT151101), and by the UK Medical Research Council (UKRI) in relation to the Emilia (MR/S001255/1) and Indigo Partnership (MR/R023697/1) awards.

Patient Consent for Publication

Not Required

ORCID iDs

Amanpreet Kaur <https://orcid.org/0000-0002-8049-1385>
Ankita Mukherjee <https://orcid.org/0000-0002-6236-1317>
Anushka Patel <https://orcid.org/0000-0003-3825-4092>
David Peiris <https://orcid.org/0000-0002-6898-3870>
Mercian Daniel <https://orcid.org/0000-0002-2583-3792>
Pallab K Maulik <https://orcid.org/0000-0001-6835-6175>
Rajesh Sagar <https://orcid.org/0000-0003-4563-7841>
Sudha Kallakuri <https://orcid.org/0000-0002-0259-483X>

REFERENCES

- 1 Gururaj G, Varghese M, Benegal V, Rao GN, Pathak K, Singh LK, Mehta RY, Ram D, Shibukumar TM, Kokane A, Lenin Singh RK, Chavan BS, Sharma P, Ramasubramanian C, Dalal PK, Saha PK, Deuri SP, Giri AK, Kavishvar AB, Sinha VK, Thavody J, Chatterji R, Akoijam MR. National Health Survey of India 2015-16: Prevalence, patterns and outcomes. Bangalore, 2016URL <http://indianmhs.nimhans.ac.in/Docs/Report2.pdf>.
- 2 Sagar R, Pattanayak RD, Chandrasekaran R, *et al*. Twelve-month prevalence and treatment gap for common mental disorders: Findings from a large-scale epidemiological survey in India. *Indian J Psychiatry* 2017; **59**:46–55.
- 3 Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. *Bull World Health Organ* 2004; **82**:858–66.
- 4 Thornicroft G, Chatterji S, Evans-Lacko S, *et al*. Undertreatment of people with major depressive disorder in 21 countries. *Br. J. Psychiatry*. 2017; **210**:119–24.
- 5 Sweetland AC, Oquendo MA, Sidat M, *et al*. Closing the mental health gap in low-income settings by building research capacity: Perspectives from Mozambique. *Ann.*

- 1
2
3 Glob. Heal. 2014; **80**:126–33.
- 4
5 6 Petersen I, Marais D, Abdulmalik J, *et al.* Imported from
6 https://academic.oup.com/heapol/issue/33/suppl_1. *Health Policy Plan* 2017;
7 **32**:699–709.
- 8
9 7 Maulik PK, Devarapalli S, Kallakuri S, *et al.* Evaluation of an anti-stigma campaign
9 related to common mental disorders in rural India: A mixed methods approach.
10 *Psychol Med* 2016; **47**:565–75.
- 11
12 8 Maulik PK, Kallakuri S, Devarapalli S, *et al.* Increasing use of mental health services in
12 remote areas using mobile technology: A pre- post evaluation of the SMART Mental
13 Health project in rural India. *J Glob Health* 2017; **7**. doi:10.7189/jogh.07.010408.
- 14
15 9 Maulik PK, Devarapalli S, Kallakuri S, *et al.* The Systematic Medical Appraisal Referral
15 and Treatment Mental Health Project: Quasi-Experimental Study to Evaluate a
16 Technology-Enabled Mental Health Services Delivery Model Implemented in Rural
17 India. *J Med Internet Res* 2020; **22**:e15553.
- 18
19 10 Tewari A, Kallakuri S, Devarapalli S, *et al.* SMART Mental Health Project: process
19 evaluation to understand the barriers and facilitators for implementation of
20 multifaceted intervention in rural India. *Int J Ment Health Syst* 2021; **15**:15.
- 21
22 11 Daniel M, Maulik PK, Kallakuri S, *et al.* An integrated community and primary
22 healthcare worker intervention to reduce stigma and improve management of
23 common mental disorders in rural India: protocol for the SMART Mental Health
24 programme. *Trials* 2021; **22**:179.
- 25
26 12 Moore GF, Audrey S, Barker M, *et al.* Process evaluation of complex interventions:
26 Medical Research Council guidance. *BMJ* 2015; **350**. doi:10.1136/bmj.h1258.
- 27
28 13 Moore G, Audrey S, Barker M, *et al.* Process evaluation of complex interventions UK
28 Medical Research Council (MRC) guidance. , 2016URL
29 <https://mrc.ukri.org/documents/pdf/mrc-phsrn-process-evaluation-guidance-final/>
30 [accessed on 2 August 2020].
- 31
32 14 Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health
32 promotion interventions: The RE-AIM framework. *Am. J. Public Health*. 1999;
33 **89**:1322–7.
- 34
35 15 Murray E, Treweek S, Pope C, *et al.* Normalisation process theory: A framework for
35 developing, evaluating and implementing complex interventions. *BMC Med* 2010;
36 **8**:63.
- 37
38 16 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity
38 measure. *J Gen Intern Med* 2001; **16**:606–13.
- 39
40 17 Pfizer.Inc. PHQ and GAD-7 Instructions INSTRUCTION MANUAL Instructions for
40 Patient Health Questionnaire (PHQ) and GAD-7 Measures. URL
41 [https://phqscreeners.pfizer.edrupalgardens.com/sites/g/files/g10016261/f/201412/i](https://phqscreeners.pfizer.edrupalgardens.com/sites/g/files/g10016261/f/201412/instructions.pdf)
42 [nstructions.pdf](https://phqscreeners.pfizer.edrupalgardens.com/sites/g/files/g10016261/f/201412/instructions.pdf) [accessed on 24 July 2020].
- 43
44 18 Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
44 generalized anxiety disorder: The GAD-7. *Arch Intern Med* 2006; **166**:1092–7.
- 45
46 19 Whiteford HA, Harris MG, McKeon G, *et al.* Estimating remission from untreated
46 major depression: a systematic review and meta-analysis. *Psychol. Med.* 2013;
47 **43**:1569–85.
- 48
49 20 Lund C, Tomlinson M, De Silva M, *et al.* PRIME: A Programme to Reduce the
49 Treatment Gap for Mental Disorders in Five Low- and Middle-Income Countries. *PLoS*
50 *Med* 2012; **9**:e1001359.
- 51
52
53
54
55
56
57
58
59
60

- 1
2
3 21 King's College London. Barriers to Access to Care Evaluation. London, 2011.
4 22 EuroQol Research Foundation. EQ-5D-3L – EQ-5D [WWW Document]. 2021.URL
5 <https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/> [accessed on 26 July 2021].
6
7 23 WHO. mhGAP Intervention Guide for mental, neurological and substance use
8 disorders in non- specialized health settings (Version 1.0). Geneva, 2010URL
9 www.who.int/mental_health/mhgap [accessed on 11 June 2020].
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Intervention prototype of SMART Mental Health

205x157mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Logic Model of SMART Mental Health
284x190mm (96 x 96 DPI)

BMJ Open

Protocol for Process Evaluation of SMART Mental Health Cluster Randomized Control Trial : An intervention for management of Common Mental Disorders in India

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058669.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Apr-2022
Complete List of Authors:	Mukherjee, Ankita; The George Institute for Global Health India, Daniel, Mercian; The George Institute for Global Health India Kallakuri, Sudha; The George Institute for Global Health Kaur, Amanpreet; The George Institute for Global Health India Devarapalli, Siddhardha; The George Institute for Global Health India Raman, Usha; University of Hyderabad, Department of Communication Thornicroft, Graham; King's College London Institute of Psychiatry Psychology and Neuroscience, Centre for Global Mental Health Centre for Implementation Science, Health Service and Population Research Department Essue, Beverley; University of Toronto Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation Praveen, D; The George Institute for Global Health India; University of New South Wales Sagar, Rajesh; All India Institute of Medical Sciences, Department of Psychiatry Kant, Shashi; All India Institute of Medical Sciences, Community Medicine Saxena, Shekhar; Harvard University T H Chan School of Public Health Patel, Anushka; George Institute for Global Health; University of New South Wales Peiris, David; The George Institute for Global Health; University of New South Wales, Maulik, Pallab; The George Institute for Global Health India; University of New South Wales
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health, Qualitative research
Keywords:	MENTAL HEALTH, PRIMARY CARE, Clinical trials < THERAPEUTICS, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Suicide & self-harm < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Protocol for Process Evaluation of SMART Mental Health Cluster Randomized Control Trial: An intervention for management of Common Mental Disorders in India

AUTHORS

Ankita Mukherjee¹, Mercian Daniel¹, Sudha Kallakuri², Amanpreet Kaur¹, Siddhardha Devarapalli², Usha Raman⁶, Graham Thornicroft⁷, Beverly M. Essue⁵, Praveen Devarasetty², Rajesh Sagar⁸, Shashi Kant⁸, Shekhar Saxena⁹, Anushka Patel³ and David Peiris³, Pallab K Maulik^{1,4}.

Corresponding Author: Pallab K Maulik, pmaulik@georgeinstitute.org.in

ABSTRACT

Introduction

In India about 95 % of individuals who need treatment for common mental disorders (CMDs) like depression, stress and anxiety and substance use are unable to access care. Stigma associated with help seeking and lack of trained mental health professionals are important barriers in accessing mental health care. Systematic Medical Appraisal, Referral and Treatment (SMART) Mental Health integrates a community-level stigma reduction campaign and task sharing with the help of a mobile-enabled electronic decision support system (EDSS)- to reduce psychiatric morbidity due to stress, depression, and self-harm in high-risk individuals. This paper presents and discusses the protocol for process evaluation of SMART Mental Health.

Methods and Analysis

The process evaluation will use mixed quantitative and qualitative methods to evaluate implementation fidelity and identify facilitators of and barriers to implementation of the intervention. Case studies of 6 intervention and 2 control clusters will be used. Quantitative data sources will include usage analytics extracted from the mHealth platform for the trial. Qualitative data sources will include FGDs and interviews with recruited participants, PHC doctors, community health workers (ASHAs) who participated in the project and local community leaders. The design and analysis will be guided by Medical Research Council (MRC)

1
2
3 framework for process evaluations, the RE-AIM framework, and the Normalisation Process
4 Theory.
5

6 7 **Ethics and Dissemination** 8

9
10 The study has been approved by the ethics committee of the George Institute for Global
11 Health, India and the Institutional Ethics Committee, All India Institute of Medical Sciences
12 (AIIMS), New Delhi.
13

14
15 Findings of the study will be disseminated through peer reviewed publications, stakeholder
16 meetings, digital and social media platforms.
17

18 19 **Trial Registration number:** 20

21
22 The trial has been registered with the Clinical Trial Registry-India (CTRI) -
23 CTRI/2018/08/015355
24
25

26 27 **Strengths and Limitations of the Study** 28

- 29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
- A strength of our study is its use of implementation science theories and guidelines for process evaluation to frame the study design
 - This study combines data from an open-source medical record system (OpenMRS) with qualitative methods to understand trends, patterns, and differences in outcome
 - One limitation could be the overlap between the implementation team and the evaluation team.

45 46 **INTRODUCTION** 47

48 India has a significant burden of mental disorders with an estimated 115 million people in
49 need of mental health care.¹ The National Mental Health Survey of India (2015-16) found
50 substance use, depressive disorders, and anxiety disorders to be prevalent in about 10% of
51 the population.¹ Despite the significant burden, access to mental health services is severely
52 limited and it is estimated that nearly 95% of individuals with common mental disorders
53 (CMDs) are unable to access care in India² leading to large treatment gaps. Studies report that
54 in low- and middle-income countries (LMICs), the treatment gap for any mental disorder is
55 between 75-85%.³ One study found that in low-resource settings such as India, only one in
56
57
58
59
60

1
2
3 every 27 individuals with depression who recognised need for treatment, could access
4 minimally adequate treatment from a trained mental health professional.⁴
5
6

7 This large treatment gap is due to several factors, on both demand and supply sides. Low
8 awareness about mental health in the community and high level of stigma related to mental
9 illness are key demand side factors for poor help-seeking for CMDs.⁵ On the supply side,
10 several systemic barriers limit access to mental health services. Among these are the lack of
11 a trained mental health workforce and absent/minimal mental health services at the primary
12 care level, inadequate supply of psychotropic drugs at primary health care facilities, and
13 limited budget for mental health care.⁶
14
15
16
17
18
19

20 Our formative research has demonstrated that addressing both supply and demand side
21 factors by conducting a community-based anti-stigma campaign and implementing a
22 technology-enabled mental health services delivery model by primary health workers, has the
23 potential to increase access to mental health care for those at risk of CMDs and reduction in
24 depression and anxiety scores.⁷⁻¹⁰ In this research, task sharing by primary health workers
25 helped facilitate the process, and technology was seen as an enabling factor in streamlining
26 delivery of mental health care.¹⁰
27
28
29
30
31
32
33

34 Based on these findings, we developed Systematic Medical Appraisal, Referral and Treatment
35 (SMART) Mental Health- a hybrid effectiveness-implementation cluster randomized
36 controlled trial (cRCT) that is being implemented in two Indian states. The cRCT protocol is
37 available elsewhere.¹¹ The goal of SMART Mental Health is to reduce psychiatric morbidity
38 due to psychological stress, depression, and risk of self-harm (collectively referred to here as
39 common mental disorders or CMDs for the project) in individuals identified at high risk of
40 these conditions. The co-**primary outcomes** are:
41
42
43
44
45
46
47

- 48 (1) the mean difference in PHQ-9 scores at 12 months in people identified at high-risk of CMDs;
49 (2) the difference in mean behaviour scores at 12 months in the total population.
50

51 In this paper, we outline the protocol for a process evaluation of the SMART Mental Health.
52 Process evaluations provide important insights into *how* an intervention is implemented,
53 leading to understanding what strategies either worked or did not work, explaining
54 differences in outcome, and to gain insights into the experience of the target population for
55 whom the intervention was designed. The aims of the process evaluation are to:
56
57
58
59
60

1. Assess implementation fidelity and understand how the intervention was implemented
2. Understand perceptions about effectiveness and acceptability of intervention components by different stakeholders
3. Identify and explain facilitators of and barriers to implementation of the intervention
4. Explain variations in outcomes and unexpected consequences across sites
5. Explain any adaptations to the intervention during the study and their possible impact on the outcomes

METHODS AND ANALYSIS

Theoretical Framework

The process evaluation has been integrated into the cRCT design with an early formative study conducted to understand the feasibility of implementing the project components. It draws on multiple theories and frameworks (Table 1). The Medical Research Council (MRC) guidelines for process evaluation will provide an overall conceptual framework¹². According to this framework, the three broad areas of enquiry in a process evaluation are ‘*implementation*’ (what is implemented and how) ; ‘*mechanism of impact*’ – (how intervention produces change) and ‘*context*’ – (how context affects implementation and outcomes). The framework also emphasises the need to spell out the key causal assumptions made in the programme theory.

Table 1: Theories to be used in the study

THEORY	ABOUT THEORY	PURPOSE OF USING THE THEORY
<i>Theory guiding overall design and conceptual framework of the process evaluation</i>		
MRC Framework ¹³	A framework for designing and carrying out process evaluation of complex interventions. Process evaluation should answer questions related to three components: <i>Implementation</i> (what is delivered and how?) <i>Mechanisms of impact</i> (how does the delivered intervention produce change?) and <i>Context</i> (how does context affect implementation and outcomes?) Along with the context and the mechanism of impact, it	The framework is used to provide the overall conceptual design of the process evaluation. The three components (implementation, mechanism of impact and context) will be the broad areas of inquiry in the process evaluation.

	emphasises the need to spell out the key <i>causal assumptions</i> or the programme theory.	
Theories that will inform specific domains of inquiry in the study		
RE-AIM ¹⁴	A framework which provides five key dimensions on which a behaviour change intervention can be evaluated. These include R each, E ffectiveness, A doption, I mplementation and M aintenance of an intervention.	The framework will be used to evaluate the 'Implementation' component of the programme.
Normalisation Process Theory ¹⁵	A theory which focuses on how complex interventions become 'normalised' or embedded in routine practice. It helps to understand facilitators and barriers in adoption and routinisation of an intervention. Includes four main components: <i>coherence (sense making)</i> , <i>cognitive participation (engagement)</i> , <i>collective action (work done for intervention to happen)</i> , and <i>reflexive monitoring (taking measure of costs and benefits of the intervention)</i> .	The model will be used to explain differences in routinisation of mHealth component in the post-trial maintenance phase.

We will also use the RE-AIM framework¹⁴ to understand and describe the reach, effectiveness, adoption, implementation and maintenance of the intervention. The Normalisation Process Theory (NPT)¹⁵ will help to understand the factors that influence integration and routinisation (becoming part of routine practice) of novel interventions in specific settings. NPT is grouped into four broad sub-constructs which influence normalisation or routinisation of novel interventions (coherence, cognitive participation, collective action, and reflexive monitoring). RE-AIM and NPT will be used to evaluate how the program was implemented to understand barriers to and facilitators of its routine use by PHC doctors, and community health workers commonly known as ASHAs (abbreviation for Accredited Social Health Activists) and community participants.

Broad thematic areas of inquiry will include the *context, implementation, and mechanism of impact* (Table 2). Under the theme 'context', social, political, cultural and health system level factors impacting on implementation of the intervention will be explored. Differences between the sites, programme adaptations that were a result of change in context (for example the COVID-19 pandemic), and site-specific barriers and facilitators that impacted the programme implementation and outcome will be enquired into. Under 'implementation' the process evaluation will assess the implementation of the two intervention components - anti stigma campaign and mHealth based service delivery- using

1
2
3 the RE-AIM parameters. It will also investigate the experiences of end users of the
4 intervention. Finally, the process evaluation will explore the 'mechanism of impact' by
5 critically examining any variations in outcomes or unexpected outcomes.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Conceptual Framework for Process Evaluation

Broad Area of Enquiry	Domains of Inquiry	Key Questions/Process Measures	Data Source
CONTEXT	Differences in context	<ul style="list-style-type: none"> What are the differences in social, economic, cultural and health system level, between the sites and among the clusters? Do contextual differences influence how program is delivered in different settings? 	Secondary data; Formative research data Interview with project staff
	Significant changes in context and programme adaptations	<ul style="list-style-type: none"> What are some of the key contextual factors which influenced the overall implementation of the intervention (e.g. COVID-19 pandemic)? What were some of the context specific adaptations that were made to address emerging challenges? 	Interview with project staff Project documentation on operational challenges
	Barriers and Facilitators	<ul style="list-style-type: none"> What are some major barriers faced in implementing the intervention components? What are some of the factors which acted as facilitators in implementation of the intervention components (anti-stigma campaign, mHealth, training and capacity building)? 	Interview with project staff
IMPLEMENTATION	Implementation fidelity	Was the intervention delivered as it was planned?	Program records and documents; Observation and rating Interview with project staff

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	<p>Intervention Reach</p>	<ul style="list-style-type: none"> • What was the coverage of the different <i>anti-stigma campaign</i> methods, in terms of: <ul style="list-style-type: none"> - Total persons reached (including gender-wise break-up) - Villages and clusters covered - Number and proportion of high-risk cohort reached - Number and proportion of non-high-risk cohort reached - Key stakeholders reached • What was the reach of the mHealth services in terms of : <ul style="list-style-type: none"> - Number and proportion of high-risk cohort in the intervention arm provided counselling or follow-up services by Accredited Social Health Activists (ASHAs)? - Number and proportion persons from high-risk cohort provided services in village level health camps - Number and proportion of high-risk cohort from the intervention arm who sought care at the PHC - Number and proportion high risk-cohort from the control arm who sought care for CMDs • What was the reach of IVRS messages to ASHAs and high- risk individuals in terms of <ul style="list-style-type: none"> - Total calls made - Calls completed as proportion of total calls 	<p>Project records and documents</p> <p>Backend data</p> <p>Interview with project staff</p> <p>Interview with ASHAs</p>
--	---------------------------	--	--

		<ul style="list-style-type: none"> - Calls not picked up as proportion of total calls - Average time of a call made <ul style="list-style-type: none"> • Did the ASHAs face any challenge in reaching out to any category of high-risk individual in their village? 	
	<p>Intervention effectiveness</p>	<ul style="list-style-type: none"> • What was the perception of the community and key stakeholders about the utility effectiveness content of the Information Education Communication (IEC) materials the anti-stigma? • What are some of the key take home messages that people absorbed from the campaign? • What was the perception of ASHAs about impact of anti-stigma campaign in their village? • What is the association between exposure to anti stigma content with changes in KAB scores and care seeking? • What is the perception of ASHAs about effectiveness of technology health mental health service delivery in managing CMD in the community? • What is the perception of PHC doctors about effectiveness of technology health mental health service delivery in managing CMD in the community? • What was the perception of ASHAs about the utility of messages received through Interactive Voice Recording System (IVRS)? 	<p>Community satisfaction survey done at the end of drama performance</p> <p>Outcome survey data; Backend data; FGD with community members</p> <p>Interview with community leaders (like elected village heads, influential village elders and religious leaders),</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	<p>Intervention acceptability and adoption</p>	<ul style="list-style-type: none"> • What was the perception of ASHAs about using Electronic Decision Support System(EDSS) for providing care (challenges, perceived benefits, potential for routine use of mHealth)? • What was the perception of PHC doctors about using EDSS for providing care (challenges, perceived benefits, potential for routine use of mHealth)? • What were the patterns of use of EDSS by ASHAs in terms of : <ul style="list-style-type: none"> - Average time take by ASHAs to administer GAD7 and PHQ 9 over time (during screening, during monitoring) - Association between gender of high-risk patient and average time taken by ASHAs to complete screening - Association between GAD7 and PHQ 9 scores and average time taken to complete test by ASHAs - Cluster-wise difference in average time taken by ASHAs to administer GAD7 and PHQ 9 - Association between ASHA’s age and education with average time taken to administer GAD 7 and PHQ9 • What were some key features of use of EDSS by PHC doctors in terms of: <ul style="list-style-type: none"> - Average time taken for diagnosis and identification of treatment plan using 	<p>Backend data</p> <p>Interview with ASHAs</p> <p>FGD with ASHAs; Interview with doctors</p> <p>Interview with PHC support staff</p> <p>Interview with health officials (ASHA co-ordinator, Chief Medical Officer)</p> <p>Patient interview</p>
--	--	---	--

		<p>Mental health Gap Action Programme (mhGAP) over time</p> <ul style="list-style-type: none"> - Association between type of CMD and time taken for diagnosis and identification of treatment plan using mhGAP • What was the perception of high-risk patients about ease of getting treatment through mHealth? 	
	<p>Post-trial maintenance</p>	<ul style="list-style-type: none"> • What was the proportion of ASHAs who continued to provide routine care compared to those who discontinued? • What are the factors which explain differences in the uptake of the intervention among ASHAs? • To what extent is patient adherence associate with routine care and follow-up provided by the ASHAs • What are the cluster level differences in number of CMD patients provided treatment during the post-trial phase? What are the factors which explain these differences? • To what extent has use of EDSS become routine practice among PHC doctors? • What are factors explain differences in adoption/ routinisation of EDSS in different PHC clusters? 	<p>Backend data</p> <p>Interview with ASHAs</p> <p>Interview with PHC doctors</p> <p>Interview with PHC support staff</p> <p>Interview with project staff</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	Health service use	<p>What are the barriers or facilitators that patient from intervention cluster face while accessing care in the PHC?</p> <p>How many high-risk individuals identified in the intervention arm did not seek care? What are factors which can explain this?</p> <p>What are the factors which explain treatment adherence among high-risk patients who sought care?</p> <p>What are the cluster-wise differences in service utilisation, treatment adherence and number of referrals to specialist centres? What are the factors which can explain this?</p>	<p>Backend data</p> <p>Interview with high-risk individuals</p> <p>Interview with ASHAs</p> <p>Interview with doctor</p> <p>Interview with project staff</p>
MECHANISM OF IMPACT	Variation in outcomes	What kind of cluster level variation is overserved in in the outcomes? What works, for whom and in what context?	<p>Outcome data</p> <p>Backend data; Interview with ASHAs</p> <p>Interview with doctor</p> <p>Interview with project staff</p>
	Unexpected outcomes	What are some unexpected outcomes and what factors can be attributed to them?	<p>Outcome data</p> <p>Backend data; Interview with ASHAs</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

			Interview with doctor Interview with project staff
--	--	--	---

For peer review only

Study setting

SMART Mental health is being implemented in 133 villages serviced by 44 randomly selected Primary Health Centres (PHC) in West Godavari district of Andhra Pradesh (South India) and Palwal and Faridabad districts of Haryana (North India).

Study design

The process evaluation will use a mixed-method multiple case study design with PHC clusters constituting a 'case'. Up to eight case studies will be included. Each case will be selected purposively based on the principle of maximum variation in terms of health service delivery context, implementation challenges and outcomes.

Intervention Description

The intervention comprises two key components; an anti-stigma campaign, and a technology-enabled mental health service intervention delivered through task sharing. The capacities of community health workers known as Accredited Social Health Activists (ASHAs) and PHC doctors will be enhanced, by providing training in identifying and managing stress, depression, or suicide risk using a technology enabled decision support system

In the ***pre-intervention phase*** ASHAs will be trained to use the EDSS to screen individuals at high risk of stress, depression, self-harm, or suicide using digital hand-held tablets. The tablets have two pre-installed, standardised screening and assessment tools- the Patient Health Questionnaire-9 (PHQ9)^{16 17} and the Generalized Anxiety Disorder -7 (GAD-7)^{17 18} questionnaire. The screening process classifies whether participants are at high risk of CMDs based on the PHQ-9 and GAD-7 scores. Because a substantial proportion of people at risk of CMDs undergo natural remission over a period of time¹⁹ a second screening of all people initially identified at high risk is undertaken by the ASHAs within six months of the first screening to identify those who remain at 'high risk'.

Additionally, a Knowledge Attitude Behaviour (KAB)²⁰ scale is administered to assess levels of stigma associated with mental disorders in the community, a Barrier to Access to Care Evaluation–Treatment Stigma (BACE-TS)²¹ questionnaire to assess stigma perceptions related to help-seeking for mental disorders and the EuroQol five-dimension scale (EQ-5D-

1
2
3 3L)²² to assess quality of life. Questions related to history of psychiatric morbidity,
4 availability of social network/support, treatment history and costs incurred in treatment
5 (which will be used for economic evaluation) are also asked.
6
7
8

9 In the **intervention phase** the two major intervention components will be implemented to
10 those PHCs randomised to receive SMART Mental Health (Figure 1). The logic model for how
11 the intervention strategy is hypothesised to meet its aims has been provided (Figure 2.).
12
13
14

15 [INSERT] FIGURE 1. STUDY SCHEMA FOR SMART MENTAL HEALTH¹¹
16

17 [INSERT] FIGURE 2. LOGIC MODEL OF SMART MENTAL HEALTH
18
19
20
21
22

23 The anti-stigma campaign uses audio-visual and print material tailored to the local community
24 and delivered to both high-risk and non-high-risk individuals, with the aim of reducing
25 negative knowledge, attitudes and behaviours related to mental disorders. The second
26 component of the intervention is a technology enabled mental health service delivery model.
27 An mHealth platform will be used for screening, diagnosis, referral, and management of CMDs
28 by community level health workers (ASHAs) and PHC doctors. Health workforce capacity
29 building is a crucial input which will be embedded throughout the intervention. The ASHAs
30 will follow-up individuals at high-risk of CMDs to support access to care from the PHC doctors.
31 When the patient reaches the PHC, the doctors will use an EDSS based on World Health
32 Organization's Mental Health Gap Action Programme Intervention Guide (mhGAP-IG)²³.
33 Clinical data will be shared between the ASHAs and doctors using a secure cloud-based server.
34 For follow-up care, the ASHAs will have an algorithm enabled priority listing that will provide
35 them with a traffic-light system to prioritise and track the progress of individuals in her village.
36 They will use this to follow up patients, paying particular attention to the highest priority
37 individuals, and enquiring about their treatment adherence and mental well-being.
38
39
40
41
42
43
44
45
46
47
48
49

50
51 Following the intervention, a **post-intervention phase** up to 9 months will assess the
52 sustainability of the intervention without external influence of the trial team. In this phase,
53 the components of the intervention will be rolled out in the control arm too. Support for
54 ASHAs and doctors by project staff will be minimal. Staff will assist ASHAs and doctors to
55
56
57
58
59
60

1
2
3 resolve any technical problems with the tabs and provide initial support and troubleshoot
4 any issues.
5

6 7 *Control arm* 8

9
10 In the control arm ASHAs will be provided with the names of individuals at high risk of CMDs
11 and they will support those individuals to seek care and provide them with relevant
12 information of mental health care providers. PHC doctors in the control arm will be informed
13 that there may be patients who may seek care for CMDs. The ASHAs and the doctors in the
14 control arm will not be provided with access to the EDSS. The anti-stigma campaign will be
15 delivered in a less extensive manner. Besides pamphlets and brochures, all the other anti-
16 stigma components will be shared with the study participants. The live drama shows however,
17 will not be conducted. Only videos of the drama will be shown. The ASHAs will draw on their
18 existing training and experience on mental health to support individuals as needed.
19
20
21
22
23
24
25

26 27 **Data Collection** 28

29
30 Quantitative data source includes analysis of the usage analytics extracted from the mHealth
31 platform. This includes (1) user metrics from each tablet used by ASHAs and PHC doctors; (2)
32 screening, and treatment data about each high-risk individual in the intervention cohort; (3)
33 data from the priority listing application (used by ASHAs) which provide information on
34 treatment status and high-risk individuals who need to be followed-up; and (4) data from the
35 interactive voice recorded system used to send messages to ASHAs and high-risk individuals
36 (to facilitate treatment adherence and follow-up). These data will be used to assess reach,
37 effectiveness, adoption, maintenance, and service utilisation of the intervention.
38
39
40
41
42
43
44

45 Qualitative data will include key informant interviews and focus group discussions with PHC
46 doctors, ASHAs, hospital administrators, service users and any other relevant stakeholders
47 such as family members of service users and community leaders. The qualitative study data
48 will explore perceptions of key stakeholders about the effectiveness and acceptability of
49 intervention components and challenges in implementation. A detailed data collection plan
50 has been discussed below (Table 3).
51
52
53
54
55
56
57
58
59
60

Table 3: Qualitative Data Collection Plan

Focus Group Discussions			
Type of Group/Individual	Some areas of inquiry	Number planned per PHC	Total Planned (-6 intervention and 2 control PHC clusters will be selected for the case study)
ASHAs	<ul style="list-style-type: none"> Facilitators and barriers experienced in delivering the intervention in the community Perception about effectiveness of different intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Perceptions on training appropriateness, effectiveness and methods Factors that influenced treatment seeking by high-risk cohort Overall experience of participating in the trial 	1	8
Project Field staff	<ul style="list-style-type: none"> Barriers or facilitators experienced in implementation of the intervention Perceived factors which explain high/low treatment seeking in different PHCs Key challenges and lessons learnt in implementation of intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Views on impact of the intervention in the community Perceptions on training appropriateness, effectiveness and methods 		3
Study participants from high-risk cohort in intervention arm who sought treatment <i>[To purposively select individuals who (1) went to PHC (2) Went to camp (3) got treated by psychiatrist (4) started treatment but discontinued]</i>	<ul style="list-style-type: none"> Perceptions about different intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Facilitators and barriers in treatment seeking Experience of care and perception about quality of care Perceived benefit if any as a result of treatment received Positive/negative experiences as a study participant Perception about benefits/effectiveness of the intervention 	2 (1 with men 1 with women)	12

Study Participants from non-high-risk cohort in the intervention arm	<ul style="list-style-type: none"> Perception about the different components of the anti-stigma campaign (eg. Live drama, pamphlets etc.) Key takeaway messages from the anti-stigma campaign Perceived changes if any related to mental health stigma Positive/negative experiences as study participant 	2 (One with men and one with women)	12
Study participants from high-risk cohort in the control arm (including both who sought treatment and who did not seek treatment)	<ul style="list-style-type: none"> Reasons for seeking or not seeking care Facilitators and barriers in the community to seeking care for CMDs Experience as a study participant 	2 (One with men and one with women)	4
TOTAL FGDs			39
In-Depth Interviews			
PHC doctors from intervention arm	<ul style="list-style-type: none"> Experience of using technology-based decision support system to diagnose and manage CMDs Challenges faced in trial participating Perceived effectiveness of intervention components (anti-stigma campaign, mHealth) in improving management of CMDs in the community. Possible facilitators and barriers to scaling up Overall experience of participating in the trial 	1	8
Village Heads/community leaders of the village	<ul style="list-style-type: none"> Their role in this programme if any Views about the programme and its impact Feedback and suggestion if any 	1	8
Study participants from high-risk cohort in intervention arm who who did not seek treatment	<ul style="list-style-type: none"> Perceptions about different intervention components like anti-stigma campaign, technology-based decision support system and use of IVRS Reasons for not seeking care Facilitators and barriers in treatment seeking Positive/negative experiences as a study participant Perception about benefits/effectiveness of the intervention 	1	12
Government health officials	<ul style="list-style-type: none"> Perception about effectiveness of the intervention in reducing treatment gap for CMDs 	2 (per district)	6

	<ul style="list-style-type: none"> • Perceived facilitators and challenges in scaling up the intervention • Their role if any in the programme 		
Total Interviews			24

At the end of the post-intervention phase, a detailed comparative case study of two PHCs will be undertaken. It will include one PHC with high utilisation of EDSS and one with low utilisation. The case study will provide insights into barriers and facilitators in adoption and routinisation of EDSS and explain differences in levels of utilisation of mHealth in different PHC clusters. Interviews with all key stakeholders (including PHC doctors, ASHAs, supervisors associated with the PHC) will be used to develop the case study.

Data Analysis

For quantitative data, basic descriptive analyses will be conducted. For qualitative data analysis interview transcripts will be read independently by two persons. A priori codes based on the conceptual framework (Table 2) will be used to code the data. Additional thematic findings emerging through the data will be added to the coding framework. Data will be coded using NVivo 12.0. Both qualitative and quantitative data across case studies will be triangulated to arrive at the findings.

PATIENT AND PUBLIC INVOLVEMENT

In the formative phase, community feedback was sought through FGDs, to make anti-stigma content culturally and contextually relevant. The study findings will be shared with the public. Findings will be disseminated through publication in peer reviewed journals, meetings, digital and social media platforms.

ETHICS AND DISSEMINATION

SMART Mental Health cRCT was approved by the George Institute for Global Health, India and the Institutional Ethics Committee (IEC), All India Institute of Medical Sciences (AIIMS), New Delhi. The trial has been registered (CTRI/2018/08/015355) with the Clinical Trial Registry-India, National Institute of Medical Statistics, Indian Council of Medical Research (ICMR). The project has received requisite approval the Health Ministry's Screening Committee (HMSC), ICMR.

TRIAL STATUS

At the time of writing this paper, the intervention phase of the trial had begun in both sites. Clinical Trials Registration was completed on 16th August 2020. Randomization of clusters in Haryana was done on 21st September 2020 and in Andhra Pradesh on 4th December 2020. Key intervention components were being delivered in Andhra Pradesh and post intervention activities and follow-up surveys were being planned in Haryana.

Authors' Affiliation

¹The George Institute for Global Health, New Delhi, India. ²The George Institute for Global Health, Hyderabad, India. ³The George Institute for Global Health, UNSW Sydney, Sydney, Australia. ⁴University of New South Wales, Sydney, Australia. ⁵ Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. ⁶ Department of Communication, University of Hyderabad, Hyderabad, India. ⁷Centre for Global Mental Health and Centre for Implementation Science, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ⁸ All India Institute of Medical Sciences, New Delhi, India, ⁹Harvard T H Chan School of Public Health, Boston, USA.

Contributors

DP, PKM and AP conceptualised the SMART Mental Health Trial with a process evaluation in mind. AM developed this process evaluation protocol with extensive and significant inputs from PKM and DP. PKM and DP commented on multiple drafts before sending a prefinal version to everyone listed as authors. The manuscript was reviewed and critical comments were provided by MD,SKI, AK, SD,UR, GT, BME, PD, RS, SK, SS and AP. All authors provided critical intellectual inputs and comments to the draft. PKM leads the implementation of the trial in India along with MD,SD, SKI, AK and AM. All authors contribute to science or operationalising of the project as co-investigators, or as steering committee members , or researchers helping in the implementation of the trial. All authors have critically reviewed, commented and approved the final manuscript.

Funding

1
2
3 This research is supported by an Australian National Health and Medical Research Council (NHMRC)
4 Global Alliances for Chronic Disease Grant (APP1143911). There is no role of the funding body in the
5 design of the study and the conceptualisation and writing of the manuscript.
6
7
8
9

10 **Competing Interest statement**

11
12 The George Institute has a part-owned social enterprise, George Health Enterprises, which has
13 commercial relationships involving digital health innovations.
14
15

16
17 PKM is partially supported through NHMRC/GACD grant (SMART Mental Health-APP1143911) and
18 UKRI/MRC grant MR/S023224/1 - Adolescents' Resilience and Treatment Needs for Mental health in
19 Indian Slums (ARTEMIS). MD, SD, SKI, AK, AM and DP are partially or wholly supported through the
20 SMART Mental Health NHMRC/GACD grant. DP is supported by fellowships from the National Health
21 and Medical Research Council of Australia (1143904) and the Heart Foundation of Australia (101890).
22
23 AK is partially supported by Indigo Partnership (MR/R023697/1) award. GT is supported by the
24 National Institute for Health Research (NIHR) Applied Research Collaboration South London at King's
25 College London NHS Foundation Trust, and by the NIHR Asset Global Health Unit award. The views
26 expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department
27 of Health and Social Care. GT is also supported by the Guy's and St Thomas' Charity for the On Trac
28 project (EFT151101), and by the UK Medical Research Council (UKRI) in relation to the Emilia
29 (MR/S001255/1) and Indigo Partnership (MR/R023697/1) awards.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Patient Consent for Publication**

47
48 Not Required
49

50 **ORCID iDs**

51
52 Amanpreet Kaur <https://orcid.org/0000-0002-8049-1385>
53 Ankita Mukherjee <https://orcid.org/0000-0002-6236-1317>
54 Anushka Patel <https://orcid.org/0000-0003-3825-4092>
55 David Peiris <https://orcid.org/0000-0002-6898-3870>
56 Mercian Daniel <https://orcid.org/0000-0002-2583-3792>
57 Pallab K Maulik <https://orcid.org/0000-0001-6835-6175>
58
59
60

Rajesh Sagar <https://orcid.org/0000-0003-4563-7841>

Sudha Kallakuri <https://orcid.org/0000-0002-0259-483X>

REFERENCES

- 1 Gururaj G, Varghese M, Benegal V, Rao GN, Pathak K, Singh LK, Mehta RY, Ram D, Shibukumar TM, Kokane A, Lenin Singh RK, Chavan BS, Sharma P, Ramasubramanian C, Dalal PK, Saha PK, Deuri SP, Giri AK, Kavishvar AB, Sinha VK, Thavody J, Chatterji R, Akoijam MR. National Health Survey of India 2015-16: Prevalence, patterns and outcomes. Bangalore, 2016URL <http://indianmhs.nimhans.ac.in/Docs/Report2.pdf>.
- 2 Sagar R, Pattanayak RD, Chandrasekaran R, *et al.* Twelve-month prevalence and treatment gap for common mental disorders: Findings from a large-scale epidemiological survey in India. *Indian J Psychiatry* 2017; **59**:46–55.
- 3 Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. *Bull World Health Organ* 2004; **82**:858–66.
- 4 Thornicroft G, Chatterji S, Evans-Lacko S, *et al.* Undertreatment of people with major depressive disorder in 21 countries. *Br. J. Psychiatry.* 2017; **210**:119–24.
- 5 Sweetland AC, Oquendo MA, Sidat M, *et al.* Closing the mental health gap in low-income settings by building research capacity: Perspectives from Mozambique. *Ann. Glob. Heal.* 2014; **80**:126–33.
- 6 Petersen I, Marais D, Abdulmalik J, *et al.* Imported from https://academic.oup.com/heapol/issue/33/suppl_1. *Health Policy Plan* 2017; **32**:699–709.
- 7 Maulik PK, Devarapalli S, Kallakuri S, *et al.* Evaluation of an anti-stigma campaign related to common mental disorders in rural India: A mixed methods approach. *Psychol Med* 2016; **47**:565–75.
- 8 Maulik PK, Kallakuri S, Devarapalli S, *et al.* Increasing use of mental health services in remote areas using mobile technology: A pre- post evaluation of the SMART Mental Health project in rural India. *J Glob Health* 2017; **7**. doi:10.7189/jogh.07.010408.
- 9 Maulik PK, Devarapalli S, Kallakuri S, *et al.* The Systematic Medical Appraisal Referral and Treatment Mental Health Project: Quasi-Experimental Study to Evaluate a Technology-Enabled Mental Health Services Delivery Model Implemented in Rural India. *J Med Internet Res* 2020; **22**:e15553.
- 10 Tewari A, Kallakuri S, Devarapalli S, *et al.* SMART Mental Health Project: process evaluation to understand the barriers and facilitators for implementation of multifaceted intervention in rural India. *Int J Ment Health Syst* 2021; **15**:15.
- 11 Daniel M, Maulik PK, Kallakuri S, *et al.* An integrated community and primary healthcare worker intervention to reduce stigma and improve management of common mental disorders in rural India: protocol for the SMART Mental Health programme. *Trials* 2021; **22**:179.
- 12 Moore GF, Audrey S, Barker M, *et al.* Process evaluation of complex interventions: Medical Research Council guidance. *BMJ* 2015; **350**. doi:10.1136/bmj.h1258.
- 13 Moore G, Audrey S, Barker M, *et al.* Process evaluation of complex interventions UK Medical Research Council (MRC) guidance. , 2016URL <https://mrc.ukri.org/documents/pdf/mrc-phsrn-process-evaluation-guidance-final/> [accessed on 2 August 2020].
- 14 Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health

- 1
2
3 promotion interventions: The RE-AIM framework. *Am. J. Public Health.* 1999;
4 **89**:1322–7.
5
6 15 Murray E, Treweek S, Pope C, *et al.* Normalisation process theory: A framework for
7 developing, evaluating and implementing complex interventions. *BMC Med* 2010;
8 **8**:63.
9
10 16 Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity
11 measure. *J Gen Intern Med* 2001; **16**:606–13.
12
13 17 Pfizer.Inc. PHQ and GAD-7 Instructions INSTRUCTION MANUAL Instructions for
14 Patient Health Questionnaire (PHQ) and GAD-7 Measures. URL
15 [https://phqscreeners.pfizer.edrupalgardens.com/sites/g/files/g10016261/f/201412/i](https://phqscreeners.pfizer.edrupalgardens.com/sites/g/files/g10016261/f/201412/instructions.pdf)
16 [nstructions.pdf](https://phqscreeners.pfizer.edrupalgardens.com/sites/g/files/g10016261/f/201412/instructions.pdf) [accessed on 24 July 2020].
17
18 18 Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
19 generalized anxiety disorder: The GAD-7. *Arch Intern Med* 2006; **166**:1092–7.
20
21 19 Whiteford HA, Harris MG, McKeon G, *et al.* Estimating remission from untreated
22 major depression: a systematic review and meta-analysis. *Psychol. Med.* 2013;
23 **43**:1569–85.
24
25 20 Lund C, Tomlinson M, De Silva M, *et al.* PRIME: A Programme to Reduce the
26 Treatment Gap for Mental Disorders in Five Low- and Middle-Income Countries. *PLoS*
27 *Med* 2012; **9**:e1001359.
28
29 21 King's College London. Barriers to Access to Care Evaluation. London, 2011.
30
31 22 EuroQol Research Foundation. EQ-5D-3L – EQ-5D [WWW Document]. 2021.URL
32 <https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/> [accessed on 26 July 2021].
33
34 23 WHO. mhGAP Intervention Guide for mental, neurological and substance use
35 disorders in non- specialized health settings (Version 1.0). Geneva, 2010URL
36 www.who.int/mental_health/mhgap [accessed on 11 June 2020].
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Study Schema for SMART Mental Health

90x90mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2: Logic Model for SMART Mental Health

90x90mm (300 x 300 DPI)